GlassScriptPhysician profile
Katie Eileen Machanda
NPI 1063542025
$2,928.16
in general payments reported to CMS, 2019-2025
27 companies · $639 in 2025
The $639 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $283 · 2021: $214 · 2022: $236 · 2023: $564 · 2024: $685 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $730.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $323.75 | 2019-2025 | |
| Abbvie INC. | $259.03 | 2022-2025 | |
| Exact Sciences Corporation | $170.08 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $166.47 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $161.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $145.11 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.97 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.80 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.72 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $85.19 | 2019-2022 | |
| Axsome Therapeutics, INC. | $84.51 | 2023-2025 | Auvelity, Sunosi |
| Dexcom, INC. | $65.72 | 2023-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $64.21 | 2020-2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $55.76 | 2019-2025 | Repatha, Prolia, Evenity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $45.75 | 2021 | |
| Abbott Laboratories | $40.18 | 2025 | Freestyle Libre 3 |
| Phadia US INC. | $31.65 | 2020-2023 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $28.06 | 2019-2022 | |
| Allergan, INC. | $26.50 | 2020 | |
| Almatica Pharma LLC | $25.88 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $20.44 | 2023 | Opsumit, Uptravi |
| Dynavax Technologies Corporation | $20.12 | 2023 | Heplisav-B |
| Lundbeck LLC | $18.63 | 2024 | Rexulti |
| Shield Therapeutics INC | $17.82 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $13.67 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Machanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.